Explore All Funded Research
Our database of currently and previously funded projects makes it easier than ever to learn about the research we fund. Search awards by keyword, pediatric brain tumor type, type of science, and institution.
Decades of Research Impact
Partners In Innovation
The Pediatric Brain Tumor Foundation works with the scientific community and patient families to identify and address critical gaps in pediatric brain tumor research. Our early-stage seed funding makes it possible for researchers to pursue bold ideas, generate the evidence needed to move promising discoveries forward, and position their work for larger-scale investment and government-funded grants.
Our investment is often just the beginning. For every $1 PBTF invests in scientific innovation, our researchers go on to secure an additional $12 in funding to advance their work — proof that strategic philanthropy can unlock resources far beyond our initial investment.
Pediatric Brain Tumor Foundation-supported research has led to transformative discoveries such as:
A New Treatment Developed Specifically for Pediatric Brain Tumor Patients
Children with brain tumors are treated with procedures and drugs developed more than 50 years ago for adults. After the Pediatric Brain Tumor Foundation’s seed funding uncovered a new way to target pediatric low-grade gliomas – the most common type of childhood brain tumor – DayOne Biopharmaceuticals (now Servier Pharmaceuticals) named targeted therapy DAY101 as their first priority for widespread development. The FDA has awarded this oral, brain-penetrant drug its Breakthrough Therapy, Rare Pediatric Disease, and Orphan Drug designations, and itbecame the first approved treatment for relapsed pediatric-low grade tumors option developed specifically for pediatric brain tumor patients, OJEMDA (®).
Faster and More Accurate Diagnoses
After identifying the need for intensive, pediatric-focused collaborations, PBTF provided the funding to launch SNO’s Pediatric Neuro-Oncology Research Conference and has served as its premier patient advocacy partner for more than a decade. This biennial meeting offers participants a dedicated opportunity to present and learn about pediatric brain tumor research advancements.
